Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Aortic valve replacement: validation of the Toronto Aortic Stenosis Quality of Life Questionnaire

D. Frank, S. Kennon, N. Bonaros, L. Stastny, M. Romano, T. Lefèvre, C. Di Mario, P. Stefàno, F. Ribichini, D. Himbert, M. Urena-Alcazar, J. Salgado-Fernandez, JJC. Castillo, B. Garcia Del Blanco, C. Deutsch, L. Sykorova, J. Kurucova, M. Thoenes,...

. 2021 ; 8 (1) : 270-279. [pub] 20201118

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21026114

AIMS: There is no quality of life tool specifically developed for patients with severe aortic stenosis (AS) to assess how this chronic condition and its treatment affect patients. The Toronto Aortic Stenosis Quality of Life Questionnaire (TASQ) has been developed to overcome this gap. The results of the validation of the TASQ in patients undergoing treatment for severe AS are presented. METHODS AND RESULTS: Prospective study at 10 centres in Europe and Canada, which enrolled 274 patients with severe symptomatic AS undergoing surgical or transcatheter aortic valve replacement. Mean TASQ score at baseline was 71.2 points and increased to 88.9 three months after aortic valve implantation (P < 0.001). Increases were seen for the emotional impact (32.0 to 39.0; P < 0.001), physical limitations (14.8 to 22.0; P < 0.001), and physical symptoms (8.5 vs. 11.0; P < 0.001) domains. Internal consistency was good/excellent for overall TASQ score (α = 0.891) and for the physical limitation, emotional impact, and social limitation domains (α = 0.815-0.950). Test-retest reliability was excellent or strong for the overall TASQ (intraclass correlation coefficient of 0.883) and for the physical symptoms, physical limitation, emotional impact, and social limitation domains (intraclass correlation coefficient of 0.791-0.895). Responsiveness was medium overall (Cohen's d = 0.637) and medium/large for physical symptoms, emotional impact, and physical limitations (0.661-0.812). Sensitivity to change was significant for physical symptoms, physical limitations (both P < 0.001), emotional impact (P = 0.003), and social limitations (P = 0.038). CONCLUSIONS: The TASQ is a new, brief, self-administered, and clinically relevant health-specific tool to measure changes in quality of life in patients with AS undergoing an intervention.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026114
003      
CZ-PrNML
005      
20211026133210.0
007      
ta
008      
211013s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ehf2.12961 $2 doi
035    __
$a (PubMed)33207035
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Frank, Derk $u Department of Internal Medicine III (Cardiology, Angiology and Critical Care), UKSH University Clinical Center Schleswig-Holstein, and DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Arnold-Heller Strasse 3, Kiel, 24105, Germany
245    10
$a Aortic valve replacement: validation of the Toronto Aortic Stenosis Quality of Life Questionnaire / $c D. Frank, S. Kennon, N. Bonaros, L. Stastny, M. Romano, T. Lefèvre, C. Di Mario, P. Stefàno, F. Ribichini, D. Himbert, M. Urena-Alcazar, J. Salgado-Fernandez, JJC. Castillo, B. Garcia Del Blanco, C. Deutsch, L. Sykorova, J. Kurucova, M. Thoenes, CM. Lüske, P. Bramlage, R. Styra
520    9_
$a AIMS: There is no quality of life tool specifically developed for patients with severe aortic stenosis (AS) to assess how this chronic condition and its treatment affect patients. The Toronto Aortic Stenosis Quality of Life Questionnaire (TASQ) has been developed to overcome this gap. The results of the validation of the TASQ in patients undergoing treatment for severe AS are presented. METHODS AND RESULTS: Prospective study at 10 centres in Europe and Canada, which enrolled 274 patients with severe symptomatic AS undergoing surgical or transcatheter aortic valve replacement. Mean TASQ score at baseline was 71.2 points and increased to 88.9 three months after aortic valve implantation (P < 0.001). Increases were seen for the emotional impact (32.0 to 39.0; P < 0.001), physical limitations (14.8 to 22.0; P < 0.001), and physical symptoms (8.5 vs. 11.0; P < 0.001) domains. Internal consistency was good/excellent for overall TASQ score (α = 0.891) and for the physical limitation, emotional impact, and social limitation domains (α = 0.815-0.950). Test-retest reliability was excellent or strong for the overall TASQ (intraclass correlation coefficient of 0.883) and for the physical symptoms, physical limitation, emotional impact, and social limitation domains (intraclass correlation coefficient of 0.791-0.895). Responsiveness was medium overall (Cohen's d = 0.637) and medium/large for physical symptoms, emotional impact, and physical limitations (0.661-0.812). Sensitivity to change was significant for physical symptoms, physical limitations (both P < 0.001), emotional impact (P = 0.003), and social limitations (P = 0.038). CONCLUSIONS: The TASQ is a new, brief, self-administered, and clinically relevant health-specific tool to measure changes in quality of life in patients with AS undergoing an intervention.
650    _2
$a aortální chlopeň $7 D001021
650    12
$a aortální stenóza $x diagnóza $x chirurgie $7 D001024
650    _2
$a lidé $7 D006801
650    _2
$a prospektivní studie $7 D011446
650    12
$a kvalita života $7 D011788
650    _2
$a reprodukovatelnost výsledků $7 D015203
650    _2
$a průzkumy a dotazníky $7 D011795
650    _2
$a výsledek terapie $7 D016896
651    _2
$a Kanada $7 D002170
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kennon, Simon $u Department of Cardiology, Barts Heart Centre, St. Bartholomew's Hospital, London, UK
700    1_
$a Bonaros, Nikolaos $u Department of Cardiac Surgery, Innsbruck Medical University, Innsbruck, Austria
700    1_
$a Stastny, Lukas $u Department of Cardiac Surgery, Innsbruck Medical University, Innsbruck, Austria
700    1_
$a Romano, Mauro $u Department of Thoracic and Cardiovascular Surgery, Department of Interventional Cardiology, Hôpital Privé Jacques Cartier, Massy, France
700    1_
$a Lefèvre, Thierry $u Department of Thoracic and Cardiovascular Surgery, Department of Interventional Cardiology, Hôpital Privé Jacques Cartier, Massy, France
700    1_
$a Di Mario, Carlo $u Department of Structural Interventional Cardiology, Department of Cardiac Surgery, Careggi University Hospital, Florence, Italy
700    1_
$a Stefàno, Pierluigi $u Department of Structural Interventional Cardiology, Department of Cardiac Surgery, Careggi University Hospital, Florence, Italy
700    1_
$a Ribichini, Flavio $u Division of Cardiology, Department of Medicine, University of Verona, Verona, Italy
700    1_
$a Himbert, Dominique $u Department of Cardiology, Bichat-Claude Bernard Hospital, Paris, France
700    1_
$a Urena-Alcazar, Marina $u Department of Cardiology, Bichat-Claude Bernard Hospital, Paris, France
700    1_
$a Salgado-Fernandez, Jorge $u Department of Cardiology, Department of Cardiovascular Surgery, Hospital Juan Canalejo, Coruña, Spain
700    1_
$a Castillo, Jose Joaquin Cuenca $u Department of Cardiology, Department of Cardiovascular Surgery, Hospital Juan Canalejo, Coruña, Spain
700    1_
$a Garcia Del Blanco, Bruno $u Department of Cardiology, Hospital Vall d'Hebron, CIBER CV, Barcelona, Spain
700    1_
$a Deutsch, Cornelia $u Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany
700    1_
$a Sykorova, Lenka $u Edwards Lifesciences, Prague, Czech Republic
700    1_
$a Kurucova, Jana $u Edwards Lifesciences, Prague, Czech Republic
700    1_
$a Thoenes, Martin $u Edwards Lifesciences, Nyon, Switzerland
700    1_
$a Lüske, Claudia M $u Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany
700    1_
$a Bramlage, Peter $u Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany
700    1_
$a Styra, Rima $u Department of Psychiatry, University Health Network, Toronto, Canada
773    0_
$w MED00197251 $t ESC heart failure $x 2055-5822 $g Roč. 8, č. 1 (2021), s. 270-279
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33207035 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133216 $b ABA008
999    __
$a ok $b bmc $g 1714970 $s 1146621
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 8 $c 1 $d 270-279 $e 20201118 $i 2055-5822 $m ESC heart failure $n ESC Heart Fail $x MED00197251
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace